Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Affectis Pharmaceuticals AG Announces Target Validation Collaboration with Mitsubishi Pharma


Munich, Germany, -- Affectis Pharmaceuticals AG announced today that it has signed a collaboration agreement with Mitsubishi Pharma Corporation for the development of novel therapeutics for the treatment of affective disorders. Under the terms of the agreement, Affectis will apply its pioneering target validation technology and its exclusive animal models for the validation of Mitsubishi Pharma’s gene targets involved in depression and anxiety.

Today, one of the major challenges in developing optimised drugs against affective disorders is the limited availability of suitable animal models and sufficient expertise in selecting promising targets and leads as well as their preclinical development. Affectis´ team has more than 10 years experience in developing, performing and interpreting behavioural assays and animal models of diseases such as depression and anxiety.

“We are very glad to bring our unique expertise into the partnership with Mitsubishi Pharma, one of the leading players of the global pharmaceutical industry,” Dr Herbert Stadler, Chief Executive Officer of Affectis Pharmaceuticals AG, comments. “Since the foundation of Affectis in late 2002, we have attracted several internationally renowned partners and continuously strengthened our position as a leading research and development organisation in the field of affective disorders.”

Dr Nakajima, Executive Officer/General Manager of the Pharmaceutical Research Unit for Mitsubishi Pharma commented: “By choosing Affectis Pharmaceuticals as solutions provider for the validation of drug targets, we are ideally positioned to speed up the development of our target pipeline and potentially provide new treatment options for affective disorders.”


Publisher Contact Information:

Affectis Pharmaceuticals AG
49 89 306 22 653
info@affectis.com

Company profile of Affectis Pharmaceuticals AG
Past press releases of Affectis Pharmaceuticals AG.

Data


26,126
Tech investments
From our Online Data Service
16,881
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices
Sep 12€9.0MSoftware development

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.